C hronic lymphocytic leukemia (CLL) is the commonest B-cell lymphoproliferative disease in the western hemisphere. There is a high degree of variation in the clinical course with some patients remaining asymptomatic for many years whilst others rapidly require treatment. A number of molecular markers including cytogenetics abnormalities, 1 immunoglobulin gene mutational status, 2,3 ZAP-70 expression 4,5 and CD38 expression [6] [7] [8] allow the prognosis of asymptomatic patients to be predicted. The regulation of expression and functions of these prognostic markers must be related, either directly or indirectly, to the clinical evolution of CLL and this relation is currently being intensively investigated. One hypothesis is that proliferation of CLL cells in patient with a poor prognosis is greater than that of cells from cases with a good prognosis and this is supported by data showing that signaling through the Bcell receptor of unmutated-CLL is greater than that of mutated-CLL. 9 Similarly, transduction of ZAP-70 in CLL cells increased proliferation. 10, 11 Signaling through CD38 has also been shown to drive CLL cell proliferation 12, 13 suggesting that signals delivered through this surface molecule cause cell division in poor prognosis CD38-expressing cases but not in CD38-negative cases.
The ligand of CD38 is platelet endothelial cell adhesion molecule-1 (PECAM-1 or CD31), 14, 15 which is expressed by both CLL cells 16, 17 and endothelial tissues. As well as driving proliferation, CD38 may, therefore, also have a role in cell adhesion. CD38 carries out an ADP-ribosyl cyclase reaction, catalyzing the cyclization of NAD to produce cyclic ADP-ribose, but the significance of this for the biology of CLL is not known. Flow cytometry shows that the expression of CD38 on CLL cells in lymph nodes is greater than that on peripheral blood cells. 18 CLL lymph nodes contain proliferation centers, containing T cells and dendritic cells as well as proliferating CLL cells and this suggests that CD38 expression is regulated by the lymph node microenvironment.
The microenvironment is critical for the growth of CLL cells, 19, 20 and several systems, using different stromal cell layers, have been used [21] [22] [23] in vitro to mimic these conditions. Seminal works 24, 25 demonstrated that cross-linking CD40 in the context of a stromal layer (human fibroblast cell line) produced proliferation of normal B cells, which could be enhanced by the addition of interleukin-4 (IL-4). In a small in vitro study CLL cells responded by proliferation to the specific combination of IL-4 with CD40 stimulation. 26 The combination of IL-4 with B-cell receptor signaling did not produce this effect. In order to study both quiescent (representing peripheral blood leukemic cells) and proliferating cells we have characterized a dual cell culture system 27 that utilizes non-transfected mouse fibroblast L-cells (NT-L) to maintain viable CLL cells and L-cells transfected with CD40 ligand (CD154) combined with IL-4 (CD154/IL-4 system) to drive their proliferation.
Design and Methods

Patients
Patients with both early stage and advanced disease were studied (Supplementary Table 1 ), provided that they had a white cell count >50×10 9 /L. At the time of study no patient had been treated for 3 months. Blood was also obtained from healthy donors. Local research ethics committee approval was obtained. Immunoglobulin gene mutational status was determined by polymerase chain reaction (PCR) amplification of the rearranged immunoglobulin gene and sequencing;
3 ≥98% homology indicates unmutated immunoglobulin genes.
Cell culture
CLL cells were isolated from peripheral blood by density gradient centrifugation, then washed and re-suspended at 3×10
6 cells/mL in RPMI1640 medium (Cambrex, UK) supplemented with 10% fetal bovine serum (Cambrex, UK), non-essential amino acids (Invitrogen, UK), antibiotics (Invitrogen, UK) and Hepes buffer (Cambrex, UK). Isolated CLL cells were then cultured in 6-well plates for 0-6 days. We utilized 30Gy irradiated mouse fibroblast Lcells or L-cells transfected with CD154 (a gift from Professor J Gordon, Birmingham) together with IL-4 (R&D Systems) at 20 ng/mL as stromal cell layers to investigate the variability in proliferative response in individual cases of CLL. When indicated, CLL cells were cultured on these stromal cell layers for up to 6 days, with changes of medium on alternate days.
Annexin V assay
The annexin V assay was performed using the BD Annexin V Apoptosis Detection Kit (BD PharMingen: San Diego, CA, USA). CLL cells were harvested, then washed with phosphate-buffered saline (PBS) and re-suspended in 100 µL annexin V binding buffer containing 10 µL fluorescein isothiocyanate (FITC)-conjugated annexin V and 10 µL propidium iodide (PI) for 15 minutes. After this time, an additional 400 µL of annexin V buffer was added and samples analyzed using flow cytometry. Results are displayed as density plots showing annexin V-FITC (FL1) versus PI (FL2) binding.
Intracellular staining
Cells (10 5 ) were harvested and washed once in PBS. After having been resuspended in 200 µL of FACS staining solution (PBS/1% bovine serum albumin [BSA], 0.05% sodium azide) anti-CD19 PE-Cy5 (BD Biosciences) and anti-CD38 FITC (BD Biosciences) were added and cells were incubated for 30 min on ice. The cells were washed twice in PBS before they were fixed in 2% paraformaldehyde for 2 hours at room temperature. After two washes cells were permeabilized with 200 µL Triton-X (0.05% in PBS) for 20 min at room temperature. An equal volume of 4% BSA in PBS was then added to the cells which were © F e r r a t a S t o r t i F o u n d a t i o n 
Western blots
Protein lysates were prepared and electrophoresis by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out according to standard techniques. After transfer to PVDF membranes staining for ZAP-70 (Abcam, ab18371) and GAPDH (Abcam) was carried out. 
Results
Regulation of CD38
Surface marker changes associated with CLL cell residence in lymph nodes, rather than in peripheral blood, have been reported and include up-regulation of CD23 29 and CD38.
18 Lymph nodes are also the sites of T-cell containing proliferation centers. The CD40 pathway, stimulated by the T-cell surface marker CD154, provides important proliferative and other signals for normal B cells and we, therefore, tested the effects of the CD154/IL-4 system on CD38 expression. We observed an increase in expression over 5 days that was not seen on culture of CLL cells with NT-L cells or on tissue culture plastic ( Figure 1A) . A direct comparison of the effects of CD154 and IL-4 showed that the up-regulation of CD38 is almost entirely due to CD154 ( Figure 1B ). We next investigated whether the effects of the CD154-L/IL-4 system were reversible ( Figure 2 ). After 2 days of culture in the CD154-L/IL-4 system, CLL cells were transferred to NT-L cells, plastic or further CD154-L/IL-4. As anticipated, the CD154-L/IL-4 system increased CD38 expression but surprisingly the NT-L cells also maintained increased expression. We cannot exclude the possibility that contaminating CD154-L cells were the cause of this but following transfer to plastic there was a decline in CD38 expression suggesting that contamination was not a major contributor. CD38 expression varies in CLL and is associated with prognosis.
2,8,30
We, therefore, compared CD38 expression induced by the CD154/IL-4 system with basal CD38 expression ( Figure  3 ). Patients at each clinical stage are able to up-regulate CD38 expression. For patients with clinical stage A CLL, the mean CD38 expression increased from 40% to 53%; for stage B the increase was from 58% to 85%. When analyzed by mutational status, CD38 expression increased from 31% to 68% for mutated cases and from 52% to 73% for unmutated cases. However, there was not a significant difference (Mann-Whitney U-test) between basal and induced CD38 expression. This demonstrates that CD38 expression can be regulated by the CLL cell environment and is not a fixed feature of the malignant clone. Similarly analysis by immunoglobulin gene mutational status showed that cases with mutated immunoglobulin genes up-regulated CD38 expression in the CD154/IL-4 system and again there was not a significant difference between basal and induced expression (Mann-Whitney Utest) ( Figure 3B ). CD38 is a signaling molecule and can drive proliferation of CLL cells. 12 We, therefore, looked for a correlation between CD38 expression and proliferation as measured by [ Figure 3C ). In addition we showed that high spontaneous apoptosis on plastic is markedly reduced by culture on either CD154/IL-4 or NT-L cells (Supplementary Figure 1) . These experiments provide evidence that: (i) CD38 expression can be regulated; (ii) stimulation by CD154/IL-4 is sufficient to increase the expression of CD38; (iii) induction is unlikely to be related to clinical stage or prognosis.
The CD154/IL-4 system activates leukemic B cells and causes an increase in cell size associated with proliferation. Flow cytometry (Supplementary Figure 2) showed that following culture in the CD154/IL-4 system both the smaller and larger cells had higher CD38 expression than that of leukemic cells cultured on plastic. However, within the CD154/IL-4-stimulated population the larger cells had higher CD38 expression than the smaller cells. Thus, CD38 expression (for each individual patient) is proportional to the degree of cell activation. Whilst an increase in the size of cells alone (rather than true up-regulation of the surface receptor) may contribute to this effect, it is unlikely to account for all the observed increase in expression. For example, we found (in accordance with others, 31 that CD5 expression decreases following CD40 stimulation (Supplementary Figure 2B) , whilst CD79B does not alter (Supplementary Figure 2C) , demonstrating that increase in size of cells is not necessarily associated with increase in surface marker expression.
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Regulation of CD38 in normal peripheral blood B cells
In order to compare the regulation of CD38 on a normal population of B cells we purified peripheral blood B cells from normal blood donors. A pool from four donors was used in subsequent experiments. Freshly isolated cells showed CD38 expression of about 65% (Figure 4 ). Over 5 days this level of expression did not change when the cells were cultured on plastic or NT-L, but as with the leukemic cells the CD154-L cells/IL-4 system induced an increased level of expression. We conclude that CD38 is a regulated surface marker in polyclonal populations of normal peripheral blood B cells.
Effects of agonistic anti-CD38 antibody
CD38 is a signaling molecule in CLL cells, and an agonistic anti-CD38 antibody (IB4) has been shown to drive proliferation. 12 In order to find out how CD38 signaling altered CD154-L cells/IL-4-stimulated signaling we cultured CLL cells either on plastic, with NT-L cells or in the CD154-L cells/IL-4 system. As previously found, CD154-L cells/IL-4 effectively drove proliferation, but IB4 did not produce an additional increment in [ (Figure 7 ). There was no induction of proliferation when CLL cells were cultured on plastic, and a modest increase only when cultured on NT-L without IL-4. We conclude that the effect of the CD154-L cells/IL-4 system is to drive proliferation at a maximum that is possible in vitro and that CD38 signaling cannot increase this further. However, viable but non-proliferating CLL cells, maintained on NT-L cells, did show an increase in proliferation with IB4 suggesting that CD38 signaling may be important in situations in which the leukemic cells are not receiving maximum signals. 
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Relationship of ZAP-70 expression to CD38 expression
It has been reported that CLL cells co-express CD38 and ZAP-70 32 and also that some of the effects of CD38 signaling may be mediated through ZAP-70 phosphorylation.
33
In order to further define the relationship between CD38 and ZAP-70 we sought to determine whether ZAP-70 expression was induced in parallel with CD38 in our CD154-L/IL-4 system. We stained cells with antibodies to the surface markers CD5, CD19 and CD38 and, after fixation and permeabilization, added anti-ZAP-70 antibody. Electronic gating defined the CD5 + CD19
+ cell population and excluded apoptotic cells and cell doublets. ZAP-70 and CD38 expression was measured on this cell population. We investigated those cases with an initial low level of CD38 expression in order to be able to observe the effects of major increases in the level of this marker. In five out of seven cases examined there was an increase in CD38 expression in the CD154/IL-4 system, accompanied by an increase in ZAP-70 expression (Figures 6 C-F) . In the cases shown there was an increase in CD38 accompanied by an increase in ZAP-70 and in all the cases analyzed (n=7) (Supplementary Table 2 ) the majority of ZAP70 + cells were also CD38 + ( Figures 6C and 6D ). However, we also found examples of discordance between induction of CD38 + and ZAP70 + . (Figure 8E demonstrates an increase in CD38 + cells without an increase in ZAP-70 expression whereas Figure 8F shows a case with increase in ZAP-70 expression without accompanying increase in CD38). Western blots are shown an accompanying the flow cytometry profiles to confirm these findings. Therefore, we show that there is a dynamic association between the increase in CD38 + cells and expression of ZAP-70 but that this linkage is not invariable. Expression of CD38 and ZAP-70 may be driven by similar stimuli but differences intrinsic to the leukemic cell may in some cases produce discordant expression of these two markers. CD38 is a multifunctional surface molecule, with potential roles in both signaling and adhesion, 33 which is expressed on activated B cells including (in humans) ger- 40 Others have demonstrated that CD38 is induced by IL-2 12 and activated T cells. 41 In this report we show, for the first time, that the T-cell surface marker, CD154, which is likely be a physiological ligand encountered by leukemic B-cells in the lymph node, is sufficient to upregulate CD38. Our data, and previous work, 12 suggest that B-cell activation by a variety of means causes up-regulation of CD38. One hypothesis generated from these data is that CD38 functions are important not only in patients who have high basal expression but also in some cases in which expression can be induced by contact with T cells in lymph nodes.
Discussion
We observed a wide variation of CD38 responses to CD154-L cells/IL-4. Recently it has been found that polymorphisms at the CD38 locus are related to prognosis in CLL and it is possible that basal or induced expression may be influenced by genetic variation. 42, 43 CD38 is expressed on between 30 and 60% of normal peripheral blood B cells. 44 We confirmed this finding and demonstrated that CD38 expression increases in the CD154/IL-4 system. These findings imply that CD38 expression can be regulated both in polyclonal normal B cells and monoclonal leukemic cell populations. It appears that the fraction of peripheral blood cells, either normal or leukemic, expressing CD38 is a function of how well this population responds to stimulation from CD154 and growth factors in either the germinal center (for normal B cells), or proliferation centers (for CLL cells). Our model postulates that B cells receive signals, in the lymph nodes or bone marrow, which induce CD38 expression and that cases with a poor clinical outcome maintain CD38 expression in the peripheral blood whilst those with a good clinical outcome rapidly lose expression of this surface marker. Our results further show that high CD38 expression in CLL is, in fact, similar to the expression observed in normal peripheral blood and suggest that, if considering this surface marker in isolation, cases of CLL that do not express CD38 are abnormal.
ZAP-70 is a prognostic marker in CLL, 4, 5 and is also expressed in normal B cells on activation.
45-47
Simultaneous measurements of CD38 and ZAP-70 at single time points and without culture in vitro have shown that the expression of these two markers is associated. 32 We have shown that expression of ZAP-70 can be induced together with CD38 expression by the CD154/IL-4 system (Supplementary Table 2 ) in a proportion of patients, although others show discordance in the induction of these two molecules ( Figure 8A and 8B). CD40 stimulation, therefore, appears to play a role in driving expression of both CD38 and ZAP-70 but other factors, some of which may be intrinsic to the leukemic cell, also function to regulate the expression of these prognostically important proteins.
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